CTLA4 and colitis: Although there were no significant differences in the PRO‐CTCAE questionnaire between the two agents, it is well documented that anti‐PD1 treatment is more frequently associated with arthritis and myocarditis, whereas anti‐CTLA4‐driven toxicities include mostly colitis, hypophysitis, and skin rash.28